CMF beneficial in HER2-positive and -negative tumours

Gespeichert in:

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2001

Schlagwörter:	Methotrexate Cyclophosphamide Fluorouracil Positive Patient Negative Patient

Anmerkung:	© Adis International Ltd 2001

Übergeordnetes Werk:	Enthalten in: Inpharma weekly - Auckland : ADIS internat., 1975, 1277(2001), 1 vom: März, Seite 10-10
Übergeordnetes Werk:	volume:1277 ; year:2001 ; number:1 ; month:03 ; pages:10-10

Links:	Volltext

DOI / URN:	10.2165/00128413-200112770-00020

Katalog-ID:	SPR036333352

Internformat


LEADER	01000caa a22002652 4500
001	SPR036333352
003	DE-627
005	20230519174652.0
007	cr uuu---uuuuu
008	201007s2001 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.2165/00128413-200112770-00020 \|2 doi
035			\|a (DE-627)SPR036333352
035			\|a (SPR)00128413-200112770-00020-e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
245	1	0	\|a CMF beneficial in HER2-positive and -negative tumours
264		1	\|c 2001
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a © Adis International Ltd 2001
650		4	\|a Methotrexate \|7 (dpeaa)DE-He213
650		4	\|a Cyclophosphamide \|7 (dpeaa)DE-He213
650		4	\|a Fluorouracil \|7 (dpeaa)DE-He213
650		4	\|a Positive Patient \|7 (dpeaa)DE-He213
650		4	\|a Negative Patient \|7 (dpeaa)DE-He213
773	0	8	\|i Enthalten in \|t Inpharma weekly \|d Auckland : ADIS internat., 1975 \|g 1277(2001), 1 vom: März, Seite 10-10 \|w (DE-627)373977859 \|w (DE-600)2127607-9 \|x 2230-6056 \|7 nnns
773	1	8	\|g volume:1277 \|g year:2001 \|g number:1 \|g month:03 \|g pages:10-10
856	4	0	\|u https://dx.doi.org/10.2165/00128413-200112770-00020 \|z lizenzpflichtig \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_SPRINGER
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_20
951			\|a AR
952			\|d 1277 \|j 2001 \|e 1 \|c 03 \|h 10-10

Indexfelder

matchkey_str	article:22306056:2001----::mbnfcaihrpstvade
hierarchy_sort_str	2001
publishDate	2001
allfields	10.2165/00128413-200112770-00020 doi (DE-627)SPR036333352 (SPR)00128413-200112770-00020-e DE-627 ger DE-627 rakwb eng CMF beneficial in HER2-positive and -negative tumours 2001 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis International Ltd 2001 Methotrexate (dpeaa)DE-He213 Cyclophosphamide (dpeaa)DE-He213 Fluorouracil (dpeaa)DE-He213 Positive Patient (dpeaa)DE-He213 Negative Patient (dpeaa)DE-He213 Enthalten in Inpharma weekly Auckland : ADIS internat., 1975 1277(2001), 1 vom: März, Seite 10-10 (DE-627)373977859 (DE-600)2127607-9 2230-6056 nnns volume:1277 year:2001 number:1 month:03 pages:10-10 https://dx.doi.org/10.2165/00128413-200112770-00020 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 AR 1277 2001 1 03 10-10
spelling	10.2165/00128413-200112770-00020 doi (DE-627)SPR036333352 (SPR)00128413-200112770-00020-e DE-627 ger DE-627 rakwb eng CMF beneficial in HER2-positive and -negative tumours 2001 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis International Ltd 2001 Methotrexate (dpeaa)DE-He213 Cyclophosphamide (dpeaa)DE-He213 Fluorouracil (dpeaa)DE-He213 Positive Patient (dpeaa)DE-He213 Negative Patient (dpeaa)DE-He213 Enthalten in Inpharma weekly Auckland : ADIS internat., 1975 1277(2001), 1 vom: März, Seite 10-10 (DE-627)373977859 (DE-600)2127607-9 2230-6056 nnns volume:1277 year:2001 number:1 month:03 pages:10-10 https://dx.doi.org/10.2165/00128413-200112770-00020 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 AR 1277 2001 1 03 10-10
allfields_unstemmed	10.2165/00128413-200112770-00020 doi (DE-627)SPR036333352 (SPR)00128413-200112770-00020-e DE-627 ger DE-627 rakwb eng CMF beneficial in HER2-positive and -negative tumours 2001 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis International Ltd 2001 Methotrexate (dpeaa)DE-He213 Cyclophosphamide (dpeaa)DE-He213 Fluorouracil (dpeaa)DE-He213 Positive Patient (dpeaa)DE-He213 Negative Patient (dpeaa)DE-He213 Enthalten in Inpharma weekly Auckland : ADIS internat., 1975 1277(2001), 1 vom: März, Seite 10-10 (DE-627)373977859 (DE-600)2127607-9 2230-6056 nnns volume:1277 year:2001 number:1 month:03 pages:10-10 https://dx.doi.org/10.2165/00128413-200112770-00020 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 AR 1277 2001 1 03 10-10
allfieldsGer	10.2165/00128413-200112770-00020 doi (DE-627)SPR036333352 (SPR)00128413-200112770-00020-e DE-627 ger DE-627 rakwb eng CMF beneficial in HER2-positive and -negative tumours 2001 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis International Ltd 2001 Methotrexate (dpeaa)DE-He213 Cyclophosphamide (dpeaa)DE-He213 Fluorouracil (dpeaa)DE-He213 Positive Patient (dpeaa)DE-He213 Negative Patient (dpeaa)DE-He213 Enthalten in Inpharma weekly Auckland : ADIS internat., 1975 1277(2001), 1 vom: März, Seite 10-10 (DE-627)373977859 (DE-600)2127607-9 2230-6056 nnns volume:1277 year:2001 number:1 month:03 pages:10-10 https://dx.doi.org/10.2165/00128413-200112770-00020 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 AR 1277 2001 1 03 10-10
allfieldsSound	10.2165/00128413-200112770-00020 doi (DE-627)SPR036333352 (SPR)00128413-200112770-00020-e DE-627 ger DE-627 rakwb eng CMF beneficial in HER2-positive and -negative tumours 2001 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis International Ltd 2001 Methotrexate (dpeaa)DE-He213 Cyclophosphamide (dpeaa)DE-He213 Fluorouracil (dpeaa)DE-He213 Positive Patient (dpeaa)DE-He213 Negative Patient (dpeaa)DE-He213 Enthalten in Inpharma weekly Auckland : ADIS internat., 1975 1277(2001), 1 vom: März, Seite 10-10 (DE-627)373977859 (DE-600)2127607-9 2230-6056 nnns volume:1277 year:2001 number:1 month:03 pages:10-10 https://dx.doi.org/10.2165/00128413-200112770-00020 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 AR 1277 2001 1 03 10-10
language	English
source	Enthalten in Inpharma weekly 1277(2001), 1 vom: März, Seite 10-10 volume:1277 year:2001 number:1 month:03 pages:10-10
sourceStr	Enthalten in Inpharma weekly 1277(2001), 1 vom: März, Seite 10-10 volume:1277 year:2001 number:1 month:03 pages:10-10
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Methotrexate Cyclophosphamide Fluorouracil Positive Patient Negative Patient
isfreeaccess_bool	false
container_title	Inpharma weekly
publishDateDaySort_date	2001-03-01T00:00:00Z
hierarchy_top_id	373977859
id	SPR036333352
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR036333352</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519174652.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2001 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.2165/00128413-200112770-00020</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR036333352</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)00128413-200112770-00020-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">CMF beneficial in HER2-positive and -negative tumours</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2001</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Adis International Ltd 2001</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Methotrexate</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cyclophosphamide</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Fluorouracil</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Positive Patient</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Negative Patient</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Inpharma weekly</subfield><subfield code="d">Auckland : ADIS internat., 1975</subfield><subfield code="g">1277(2001), 1 vom: März, Seite 10-10</subfield><subfield code="w">(DE-627)373977859</subfield><subfield code="w">(DE-600)2127607-9</subfield><subfield code="x">2230-6056</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:1277</subfield><subfield code="g">year:2001</subfield><subfield code="g">number:1</subfield><subfield code="g">month:03</subfield><subfield code="g">pages:10-10</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.2165/00128413-200112770-00020</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">1277</subfield><subfield code="j">2001</subfield><subfield code="e">1</subfield><subfield code="c">03</subfield><subfield code="h">10-10</subfield></datafield></record></collection>
ppnlink_with_tag_str_mv	@@773@@(DE-627)373977859
format	electronic Article
delete_txt_mv	keep
collection	springer
remote_str	true
illustrated	Not Illustrated
issn	2230-6056
topic_title	CMF beneficial in HER2-positive and -negative tumours Methotrexate (dpeaa)DE-He213 Cyclophosphamide (dpeaa)DE-He213 Fluorouracil (dpeaa)DE-He213 Positive Patient (dpeaa)DE-He213 Negative Patient (dpeaa)DE-He213
topic	misc Methotrexate misc Cyclophosphamide misc Fluorouracil misc Positive Patient misc Negative Patient
spellingShingle	misc Methotrexate misc Cyclophosphamide misc Fluorouracil misc Positive Patient misc Negative Patient CMF beneficial in HER2-positive and -negative tumours
topic_unstemmed	misc Methotrexate misc Cyclophosphamide misc Fluorouracil misc Positive Patient misc Negative Patient
topic_browse	misc Methotrexate misc Cyclophosphamide misc Fluorouracil misc Positive Patient misc Negative Patient
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Inpharma weekly
hierarchy_parent_id	373977859
hierarchy_top_title	Inpharma weekly
isfreeaccess_txt	false
familylinks_str_mv	(DE-627)373977859 (DE-600)2127607-9
title	CMF beneficial in HER2-positive and -negative tumours
ctrlnum	(DE-627)SPR036333352 (SPR)00128413-200112770-00020-e
title_full	CMF beneficial in HER2-positive and -negative tumours
journal	Inpharma weekly
journalStr	Inpharma weekly
lang_code	eng
isOA_bool	false
recordtype	marc
publishDateSort	2001
contenttype_str_mv	txt
container_start_page	10
container_volume	1277
format_se	Elektronische Aufsätze
doi_str_mv	10.2165/00128413-200112770-00020
title_sort	cmf beneficial in her2-positive and -negative tumours
title_auth	CMF beneficial in HER2-positive and -negative tumours
abstract	© Adis International Ltd 2001
abstractGer	© Adis International Ltd 2001
abstract_unstemmed	© Adis International Ltd 2001
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20
container_issue	1
title_short	CMF beneficial in HER2-positive and -negative tumours
url	https://dx.doi.org/10.2165/00128413-200112770-00020
remote_bool	true
ppnlink	373977859
mediatype_str_mv	c
isOA_txt	false
hochschulschrift_bool	false
doi_str	10.2165/00128413-200112770-00020
up_date	2024-07-03T17:02:43.619Z
_version_	1803578154541907968
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR036333352</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519174652.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2001 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.2165/00128413-200112770-00020</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR036333352</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)00128413-200112770-00020-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">CMF beneficial in HER2-positive and -negative tumours</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2001</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Adis International Ltd 2001</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Methotrexate</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cyclophosphamide</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Fluorouracil</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Positive Patient</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Negative Patient</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Inpharma weekly</subfield><subfield code="d">Auckland : ADIS internat., 1975</subfield><subfield code="g">1277(2001), 1 vom: März, Seite 10-10</subfield><subfield code="w">(DE-627)373977859</subfield><subfield code="w">(DE-600)2127607-9</subfield><subfield code="x">2230-6056</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:1277</subfield><subfield code="g">year:2001</subfield><subfield code="g">number:1</subfield><subfield code="g">month:03</subfield><subfield code="g">pages:10-10</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.2165/00128413-200112770-00020</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">1277</subfield><subfield code="j">2001</subfield><subfield code="e">1</subfield><subfield code="c">03</subfield><subfield code="h">10-10</subfield></datafield></record></collection>
score	7.399473

Nicht das Richtige dabei?

Schreiben Sie uns!

CMF beneficial in HER2-positive and -negative tumours

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?